Product Images Divalproex Sodium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Divalproex Sodium NDC 55154-4154 by Cardinal Health 107, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

bag label - 5E59609F D79D 414B A6FC 7EFB1BA5B200 00

bag label - 5E59609F D79D 414B A6FC 7EFB1BA5B200 00

Divalproex sodium delayed-release tablets, USP are available in a package of 10 tablets, with each tablet containing 500mg of Valproic Acid. The tablets are pink in color and have "798" imprinted with black ink on one side for identification purposes. A prescription is required to obtain the medication, and it is advised to refer to the product insert for dosage, precautions, and warnings. The medication is manufactured by Sun Pharmaceutical Industries Ltd in Gujarat, India, and distributed by its subsidiary Sun Pharmaceutical Industries Inc, and Major Pharmaceuticals, which is distributed by Cardinal Health, all in the USA. The medication should be stored at temperatures between 20° to 25°C (68° to 77°F), with controlled excursions allowed to 15° to 30°C (59° to 86°F). The packaging is light-resistant and dispensed with a medication guide. The unit dose packaging is not considered child-resistant and is intended for institutional use only.*

spl-divalproex-figure-1 - spl divalproex figure 1

spl-divalproex-figure-1 - spl divalproex figure 1

spl-divalproex-figure-2 - spl divalproex figure 2

spl-divalproex-figure-2 - spl divalproex figure 2

This is a graph figure showing the reduction in CPS rate for patients receiving DVPX compared to placebo. The graph shows percentages ranging from -100% to 100% with the CPS rate reduction expressed as positive percentages and worsening expressed as negative percentages. The horizontal axis shows the percentage of patients and the vertical axis shows the improvement, no change, or worsening of the CPS rate reduction. There is no additional information available in the text.*

spl-divalproex-figure-3 - spl divalproex figure 3

spl-divalproex-figure-3 - spl divalproex figure 3

spl-divalproex-figure-4 - spl divalproex figure 4

spl-divalproex-figure-4 - spl divalproex figure 4

spl-divalproex-structure - spl divalproex structure

spl-divalproex-structure - spl divalproex structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.